CD274 and neoplasm: ICIs amplify the host T cell response against tumour antigens by targeting specific inhibitory signals in the T cell regulatory pathways, such as cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1).